Health PR
Key learnings from WFH
At VIVA! Communications, we live and breathe health + wellness, which is reflected in our clientele, projects and office culture. The importance of maintaining mental and physical wellbeing was even more important during the COVID-19 lockdown and working from home (WFH) environment. VIVA! implemented a variety of virtual practices during WFH to boost the team’s…
Read MoreUnderstanding the impact of COVID-19 on Australians living with an eating disorder
Approximately one-in-20 Australians, and an estimated four to eight per cent of the Australian adult population, are living with an eating disorder. As the COVID-19 pandemic continues to evolve day by day, the InsideOut Institute for Eating Disorders has just launched an online survey to better understand how people living with an eating disorder are…
Read MoreImproving clinical standards for the screening, diagnosis & management of osteoporosis across APAC
The Asia Pacific Consortium on Osteoporosis (APCO), comprising 39 clinical experts from 19 countries and regions across Asia Pacific (APAC), and its proposed ‘Framework’ aims to drive, and facilitate benchmarking for the provision of quality osteoporosis care across the region. According to a co-authored APCO member and Chair viewpoint article published on Monday, June 22,…
Read MoreTop tips for WFH video calls
How to avoid faux pas & respect your fellow zoomies Working from home presents unique challenges and opportunities for those fortunate enough to be able to do so. Businesses and their employees are doing their best to navigate these unprecedented times, so it’s important to practice patience and respect. Here at VIVA! we are doing…
Read MoreAussies & Kiwis with incurable blood cancer receive newly subsidised treatment option
Today, VIVA! partnered with Celgene, a Bristol-Myers Squibb company, Multiple Myeloma Australia and Multiple Myeloma New Zealand to announce a newly reimbursed treatment option for Australians and New Zealanders living with incurable blood cancer, multiple myeloma. REVLIMID® (lenalidomide) – the first and only maintenance treatment in ANZ specifically indicated and reimbursed for those with newly…
Read More